Celanese Corporation (CE), a key player in the bio-tech industry, has witnessed some significant developments affecting its market standing and financial metrics.
Robust cash flow,
deleveraging in 2023,
force Majeure due to supply disruptions and
quarterly dividends of $0.70 per share are some of the notable updates. The bio-tech firm has also
underperformed several times when compared to competitors and faced
challenges in China and EU markets, leading to a downgrade by Piper Sandler. Nonetheless, some investors consider it a good long-term value stock. The
financial results of Q1 and Q4 2023 and Q1 and Q2 2024 offer a detailed financial backdrop. Notably,
CE's intrinsic value has been projected at
$210.26 as of August 31, 2024. The corporation has seen various management moves, including the
appointment of former Chevron Phillips CEO and Bruce Chinn to the board of directors. Additionally, Kim K.W. Rucker has been announced as the new Lead Independent Director. CE has initiated prominent ventures including a
carbon capture project in Texas and a collaboration with Under Armour to develop a new fiber for performance stretch fabrics.
Celanese Corporation CE News Analytics from Wed, 27 Dec 2023 08:00:00 GMT to Sun, 08 Sep 2024 13:21:52 GMT -
Rating 0
- Innovation -3
- Information 4
- Rumor -5
